A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumour or Lymphoma (MK-3475-051/KEYNOTE-051)

Official Title

A Phase I/II Study of Pembrolizumab (MK-3475) in Children With Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumour or Lymphoma (KEYNOTE-051)


This is a two-part study of pembrolizumab (MK-3475) in pediatric participants who have any of the following types of cancer: - advanced melanoma (6 months to <18 years of age), - advanced, relapsed or refractory programmed death-ligand 1 (PD-L1)-positive malignant solid tumour or other lymphoma (6 months to <18 years of age), - relapsed or refractory classical Hodgkin lymphoma (rrcHL) (3 years to <18 years of age), or - advanced relapsed or refractory microsatellite-instability-high (MSI-H) solid tumours (6 months to <18 years of age). Part 1 will find the maximum tolerated dose (MTD)/maximum administered dose (MAD), confirm the dose, and find the recommended Phase 2 dose (RP2D) for pembrolizumab therapy. Part 2 will further evaluate the safety and efficacy at the pediatric RP2D. The primary hypothesis of this study is that intravenous (IV) administration of pembrolizumab to children with either advanced melanoma; a PD-L1 positive advanced, relapsed or refractory solid tumour or other lymphoma; advanced, relapsed or refractory MSI-H solid tumour; or rrcHL, will result in an Objective Response Rate (ORR) greater than 10% for at least one of these types of cancer. With Amendment 8, enrollment of participants with solid tumours and of participants aged 6 months to <12 years with melanoma were closed. Enrollment of participants aged ≥12 years to ≤18 years with melanoma continues. Enrollment of participants with MSI-H solid tumours also continues.

Trial Description

Primary Outcome:

  • Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) per Site Assessment (Melanoma, Solid Tumour and Lymphoma Participants)
  • Number of Participants with Dose-Limiting Toxicities (DLTs)
  • Number of Participants Experiencing Adverse Events (AEs)
  • Number of Participants Discontinuing Study Drug Due to AEs
  • ORR by International Working Group (IWG) Response Criteria (Cheson, 2007) per Blinded Independent Central Radiology Assessment (rrcHL Participants)
Secondary Outcome:
  • ORR by IWG Response Criteria (Cheson, 2007) per Site Assessment (rrcHL Participants)
  • Area Under the Concentration Curve (AUC) for Pembrolizumab

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society